Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

Posted in Industry News on 2nd Mar 2018

Biogen and AbbVie have announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that given the nature and complexity of adverse events being reported, characterising the evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.

Biogen believes the voluntary worldwide withdrawal of ZINBRYTA, a treatment for relapsing multiple sclerosis, is in the best interest of patients. Biogen and AbbVie continue to prioritise patient safety and the care of multiple sclerosis patients worldwide.

Alfred Sandrock, Executive Vice President and Chief Medical Officer at Biogen

Biogen will continue to work collaboratively with regulatory authorities in the withdrawal of product and with healthcare providers worldwide in their support of ZINBRYTA patients.

About ZINBRYTA

ZINBRYTA (daclizumab) is currently available in the EU, US, Switzerland, Canada and Australia. ZINBRYTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS). Because of its risks, ZINBRYTA is generally used in people who have tried two or more MS medicines that have not worked well enough. It is not known if ZINBRYTA is safe and effective for use in children under 18 years of age.

SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

This website is for medical professionals only.